Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Authors' Reply

被引：0

作者：

Hatanaka, Takeshi ^{[1
]}

Kakizaki, Satoru ^{[2
,3
]}

Hiraoka, Atsushi ^{[4
]}

Tada, Toshifumi ^{[5
,6
]}

Kumada, Takashi ^{[7
]}

机构：

[1] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Japan

[2] NHO Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Japan

[3] Gunma Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Maebashi, Japan

[4] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan

[5] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Japan

[6] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Gastroenterol, Kobe, Japan

[7] Gifu Kyoritsu Univ, Ogaki, Japan

来源：

关键词：

D O I：

10.1111/apt.18319

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1469 / 1470

页数：2

共 21 条